Hypomethylation of the interleukin-10 gene in breast cancer tissues

The Breast : Official Journal of the European Society of Mastology
Keun Su SonJungsil Ro

Abstract

The purpose of the study was to evaluate the methylation status of the interleukin-10 (IL-10) gene in breast cancer tissues compared with normal and benign breast disease tissues. Between 2000 and 2001, we used paraffin-embedded specimens of 30 normal, 31 benign and 72 breast cancer tissues from the National Cancer Center, Korea. The methylation patterns of the IL-10 gene were evaluated using bisulfite DNA sequencing and the expression levels of IL-10 mRNA were evaluated using real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) and reverse transcriptase-polymerase chain reaction (RT-PCR). The methylation rates of the IL-10 gene were significantly lower in malignant tumors than in benign and normal tissues (normal; 63.3%, benign; 74.2%, cancer; 45.8%, p = 0.02). The methylation density rates of the IL-10 gene were also significantly lower in malignant tumors (normal; 59.68 ± 7.12%, benign; 48.89 ± 7.45%, cancer; 30.56 ± 4.18%, p = 0.001). Tissues with aberrant methylation of the IL-10 gene showed significantly lower rates of mRNA expression compared with unmethylated cases (12.5% vs. 68.0%, p = 0.012). The mRNA expression of tissues with unmethylated IL-10 was upregulated approximately ten thousand-fold compared ...Continue Reading

References

Sep 1, 1995·Cancer Research·M HuangS M Dubinett
Mar 1, 1994·The Journal of Pathology·C O'Sullivan, C E Lewis
Jan 1, 1993·Annual Review of Immunology·K W MooreT R Mosmann
Nov 14, 1997·International Journal of Cancer. Journal International Du Cancer·A J MarrogiS M Freeman
Aug 24, 1999·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·S HuangM Bar-Eli
Aug 2, 2001·Neuroscience Letters·P CuevasG Giménez-Gallego
Nov 21, 2001·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·J H KangH S Kang
Apr 30, 2003·Japanese Journal of Cancer Research : Gann·Teiichiro HondaYoshinori Murakami
Nov 13, 2003·International Journal of Oncology·Yasuhiro OshimoWataru Yasui
Jan 21, 2004·Nature Reviews. Cancer·Andrew P Feinberg, Benjamin Tycko
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pouya PakneshanShafaat A Rabbani
May 20, 2004·The Journal of Biological Chemistry·Pouya PakneshanShafaat A Rabbani
Nov 18, 2004·Immunological Reviews·Mark J SmythYoshihiro Hayakawa
Dec 3, 2004·Human Molecular Genetics·Jordi FrigolaMiguel A Peinado
May 29, 2008·International Journal of Cancer. Journal International Du Cancer·Ivan ShaboJoar Svanvik

❮ Previous
Next ❯

Citations

Nov 8, 2011·Breast Cancer Research and Treatment· HamidullahRituraj Konwar
Sep 22, 2016·Indian Journal of Surgical Oncology·Hemanga Kumar BhattacharjeeMahesh C Misra
Oct 4, 2013·Pharmacogenomics·Gregorio Antonio Alcazar-GonzálezHugo Alberto Barrera-Saldaña
Jun 26, 2020·Frontiers in Immunology·Zhonghua ZhengShiwei Duan
Aug 21, 2019·Cancers·Rakesh KumarM Radhakrishna Pillai
Aug 28, 2020·Frontiers in Oncology·Susana Romero-GarciaAngeles Carlos-Reyes
Oct 20, 2020·Journal of Cellular and Molecular Medicine·Hongkai ZhuangBaohua Hou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.